1 friday, april 19 Biochemistry and Molecular Biology asbmb graduate and postdoctoral travel award keynote lecture special Session

J. Wang. Univ.of Washington.

10:00  Impaired monoamine and organic cation uptake in 

choroid plexus in mice with targeted disruption of the 

plasma membrane monoamine transporter (Slc29a4) 

gene. 

H. Duan and J. Wang. Univ. of Washington. 

(891.7)

10:20 

Organic cation transporters and the plasma membrane 

monoamine transporter: uncovering novel targets to 

treat depression. 

L. C. Daws. Univ. of Texas Hlth. Sci. 

Ctr. at San Antonio.

10:50 

Role of organic cation transporter-3 in stress effects on 

cocaine reinstatement. 

P. J. Gasser. Marquette Univ.

11:20 

Neurotoxicity in animal models of Parkinson’s disease is 

mediated by the organic cation transporter-3. 

K. Tieu. 

Plymouth Univ., Peninsula Sch. of Med. and Dent.

263.  ADVANCING DISCOVERIES FROM THE 

ACADEMIC LABORATORY TO THE MARKET

Symposium

(Sponsored by: The Divisions for Drug Discovery and 

Development and Pharmacology Education)

m

on

. 9:30 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 106

C

haired

: r. l

eaDley

Career Development

9:30 

Intellectual property protection: what, when, and how to 

protect and share your discovery. 

W. Gould.

10:05  Regulatory hurdles from bench to bedside. 

R. L. 

Dundore. InfaCare Pharmaceut. Corp.

10:40  What to know when working with technology transfer 

offices. 

R. J. Shebuski, Sr. Cardiovasc. Res. 

Consulting LLC.

11:15  Licensing: Do you have what they really want? 

C. 

Vlahos. Lilly Res. Labs.

11:50 Discussion.

PATHOLOGY/PHARMACOLOGY MONDAY

73

M

O

N

264.  NOVEL DYNAMICS OF CAMP: TOWARDS 

NEW THERAPEUTIC INTERVENTIONS 

THROUGH COMPARTMENTALIZED SIGNALING 

NETWORKS

Symposium

(Cosponsored by: The British Pharmacological Society 

and the ASPET Division for Molecular Pharmacology)

m

on

. 9:30 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 107aB

C

haired

: m. s

ChmiDt

 

anD

 m. p

eters

-G

olDen

9:30 

Cyclic nucleotide signaling in subcellular compartments. 

M. Zaccolo. Univ. of Oxford, Balliol Col.

9:55  Adenylyl cyclase as orchestrators of cAMP 

microdomains. 

D.M.F. Cooper. Univ. of Cambridge.

10:20  Cell signaling in space and time. 

J. D. Scott. Univ. of 

Washington.

10:45  Structure, function and inhibition of G protein-coupled 

receptor kinases. 

J. Tesmer. Univ. of Michigan.

11:10 

Dysregulation of cAMP networks in fibrotic lung disease. 

M. Peters-Golden. Univ. of Michigan Med. Sch.

11:35 

Developing pharmacological probes targeting exchange 

protein directly activated by cAMP. 

X. Cheng, T. 

Tsalkova and F. Mei. Univ. of Texas Med. Branch. 

(656.3)

11:45  Modulation of the cAMP pathway by Pseudomonas 

aeruginosa quorum sensing molecules. 

L. Stoddart, 

W. Coward, P. Williams and S. Hill. Univ. of 

Nottingham Sch. of Molec. Med. Sci. 

(656.4)

11:55 Discussion.

265.  ROLE OF THE COAGULATION CASCADE IN 

TISSUE INJURY AND DISEASE

Symposium

(Sponsored by: The Divisions for Toxicology; and 

Integrative Systems, Translational and Clinical 

Pharmacology)

m

on

. 9:30 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 108

C

haired

: J.p. l

uyenDyK

9:30 

Host prothrombin and fibrinogen are critical determinants 

of pathogen toxicity and host tissue damage following 

S. aureus infection. 

M. J. Flick. Cincinnati Children’s 

Hosp.

10:05  Fibrinogen: a biomarker and therapeutic candidate in 

kidney damage. 

V. S. Vaidya. Harvard Med. Sch.

10:40  Contribution of coagulation proteases to the vascular 

inflammation in sickle cell disease. 

R. Pawlinski. 

Univ. of North Carolina at Chapel Hill.

11:15  Liver let die: coagulation decides. 

J. P. Luyendyk. 

Michigan State Univ.

11:50 Discussion

266.  FATTY ACID ACTIVATION OF G PROTEIN-

COUPLED RECEPTORS: BASIC AND CLINICAL 

PERSPECTIVES

Symposium

(ASPET gratefully acknowledges the support of an 

educational grant from the Institut de Reserches and 

Janssen Research and Development, LLC)

m

on

. 9:30 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 109a

C

haired

: G. m

illiGan

 

anD

 C. B

risCoe

9:30 

Overview of the free fatty acid receptor family and the 

enigma of GPR120. 

C. Briscoe. Janssen.

10:05 

Developing novel ligands for free fatty acid receptors. 

G. 

Milligan. Univ. of Glasgow.

10:40 

GPR40 as a potential target for the treatment of type 2 

diabetes. 

V. Poitout. Univ. of Montreal.

11:15  GLPG0974, a selective FFA2 antagonist: a promising 

approach for treatment of neutrophil driven disorders? 

J. Beetens. Galapagos NV.

11:50  Phosphorylation and internalization of short splicing 

variant of the omega 3 fatty acid sensor,GPR120. 

O.B. Sanchez-Reyes, J.A. Castillo-Badillo, M.T. 

Romero-Avila, Y. Takei, A. Hirasawa, G. Tsujimoto, 

R. Villalobos-Molina and J.A. García-Sáinz. UNAM, 

Mexico City, Grad. Sch. of Pharmaceut. Sci. , Kyoto 

Univ. and Col. Fac.-Iztacala, UNAM, Tlalnepantla. 

(1173.5)

267.  CANADIAN SOCIETY OF PHARMACOLOGY 

AND THERAPEUTICS TRAINEE ORAL 

PRESENTATIONS

Oral

m

on

. 9:30 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 109B

C

haired

: F. p

arKinson

9:30 Introduction. 

F. Parkinson. Canadian Soc. of Pharmacol. 

and Therapeut.

9:35 

Pharmacogenomics of vincristine-induced neurotoxicity 

in pediatric cancer patients. 

U. Amstutz. Univ. of 

British Columbia.

9:50 

Characterization of the vascular phenotype of the 

equilibrative nucleoside transporter 1 knockout 

mouse. 

K. A. Best. Western Univ.

10:05  Genetic and clinical determinants of CYP3A4 activity 

in patients using 4

b-hydroxycholesterol as an in vivo 

probe. 

I. Y.  Gong. Western Univ.

10:20 

Tricyclic compounds inhibit the OATP1A2 transporter. 

J. 

Lu. Univ. of Montreal.

10:35 Discussion.

10:45  Therapeutic use of eNOS/Caveolin-1 antagonistic 

peptides for endothelial dysfunction and 

atherogenesis. 

A. Sharma. Univ. of British Columbia.

11:00  Pharmacogenetics of warfarin safety and effectiveness 

in children. 

K. Shaw. Univ. of British Columbia.

11:15  Decreased nuclear receptor activity mediates down-

regulation of drug metabolizing enzymes in chronic 

kidney disease through epigenetic modulation. 

T. 

Velenosi. Western Univ.

MONDAY PHARMACOLOGY

74

11:30  Surgery-induced inflammation reduces morphine 

distribution into cerebrospinal fluid. 

Y. Wang. 

Dalhousie Univ., Canada.

11:45 Discussion.

268.  CANADIAN SOCIETY OF PHARMACOLOGY 

AND THERAPEUTICS AWARD RECIPIENT 

LECTURES

m

on

. 1:30 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 109B

C

haired

: F. p

arKinson

1:30 

Senior Investigator Award Recipient.

 R. Tyndale. Univ. 

of Toronto.

2:30 

Piafsky Young Investigator Award Recipient.

 B. Le Foll. 

Univ. of Toronto.

3:30 

Distinguished Service and Education Award.

  J. Gray. 

Halifax, Nova Scotia.

269.  DRUG METABOLISM EARLY CAREER 

ACHIEVEMENT AWARD LECTURE

m

on

. 2:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 108

The Drug Metabolism Early Career Scientist Award was 

established by ASPET’s Division for Drug Metabolism to recognize 

excellent original research by early career investigators in the 

area of drug metabolism and disposition. Dr. Nina Isoherranen 

was selected for her pioneering work in understanding complex 

drug-drug interactions and in understanding the role of drug 

metabolism during pregnancy and fetal development.

2:00 Introduction. 

K. Thummel. Univ. of Washington.

2:05 

The biochemistry and clinical significance of CYP26 

enzymes in regulating retinoic acid homeostasis. 

N. 

Isoherranen. Univ. of Washington.

270.  DRUG METABOLISM DIVISION JAMES 

GILLETTE AWARD AND PLATFORM SESSION

Oral

m

on

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 108

C

haired

: W. B

aCKes

 

anD

 J. J

ones

3:00 

 

Chair’s introduction.

3:05 

270.1 

Impact of development and genetic variation on 

human hepatic CYP2B6 expression and activity. 

A. Gaedigk, 

G.P. Twist, R. Gaedigk, H. Dai, A.K. Riffel, J.S. Leeder and 

R.E. Pearce. Children’s Mercy Hosp. & Clins., Kansas City, 

MO.

3:20 

270.2 

Differences in the catalytic properties of 

CYP2B6s between common marmoset and human. 

S. 

Narimatsu, K. Mayumi, N. Hanioka, K. Masuda, S. Naito 

and A. Miyata. Grad. Sch. of Med., Dent. and Pharmaceut. 

Sci., Okayama Univ., Sch. of Pharm., Shujitsu Univ., Otsuka 

Pharmaceut. Factory and Grad. Sch. of Med. and Dent., 

Kagoshima Univ., Japan.

3:35 

270.3 

The effect of obesity and development on in 

vitro hepatic metabolism. 

G. Danielson, M. Chiney, H. Tam 

and L. Johnson. Univ. of Minnesota, Minneapolis.

3:50 

270.4 

Transport by OATP1B1 and OATP1B3 

enhances cytotoxicity of EGCG and certain substituted 

quercetins. 

Y. Zhang, A. Hays, A. Noblett, M. Thapa, D.H. Hua 

and B. Hagenbuch. Univ. of Kansas Med. Ctr. and Kansas 

State Univ.

4:05 

270.5 

Evidence for epigenetic regulation of UGT1A1 

protein expression and activity in healthy human livers. 

U. 

Yasar, D.J. Greenblatt, C. Guillemette and M.H. Court. Tufts 

Univ. Sch. of Med. and CHUQ, Laval Univ., Canada.

4:20 

270.6 

Active site gating controls substrate selectivity 

in cytosolic sulfotransferases. 

I.T. Cook, T. Wang, C.N. Falany 

and T. Leyh. Albert Einstein Col. of Med. and Univ. of Alabama 

at Birmingham.

4:35 

270.7 

The role of FcRn in the disposition, metabolism 

and pharmacokinetics of soluble non-crosslinking immune 

complexes. 

H.M. Alvarez , O-Y. So, S. Hsieh, N. Shinsky-

Bjorde, H. Ma, Y. Song, Y. Pang, M. Marian and E. Escantón. 

Merck Res. Labs., Palo Alto.

5:00 

270.8 

Vitamin D receptor activation enhances 

benzo[a]pyrene metabolism via CYP1A1 expression in 

macrophages. 

M. Matsunawa, D. Akagi, S. Uno, K. Endo-

Umeda, K. Ikeda and M. Makishima.

271.  NEUROPHARMACOLOGY DIVISION 

POSTDOCTORAL SCIENTIST AWARD 

FINALISTS

Oral

m

on

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 106

3:00 

Cannabinoid 1 receptor as therapeutic target in 

preventing chronic epilepsy. 

R. Di Maio. Univ. of 

Pittsburgh. 

(660.2)

3:20 

Dimerization of G-protein coupled receptors in appetite 

regulation and food reward. 

H. Schellekens, T.G. 

Dinan and J.F. Cryan. Sch. of Pharm., University Col. 

Cork and Food for Hlth. Ireland, Cork. 

(881.3)

3:40 

GPR158 and GPR179: a subfamily of orphan GPCRs 

as a new class of G protein signaling modulators. 

C. 

Orlandi, I. Masuho, E. Posokhova, Y. Cao, T. Ray, N. 

Hasan, R. Gregg and K. Martemyanov. The Scripps 

Res. Inst., Jupiter, FL and Univ. of Louisville. 

(1095.2)

4:00 

Increased plasma ammonia concentration contributes 

to methamphetamine-induced blood-brain barrier 

damage. 

N.A. Northrop, L.E. Halpin and B.K. 

Yamamoto. Univ. of Toledo Col. of Med. (653.2)

4:20  Amphetamine and methamphetamine differentially 

regulate biophysical properties of dopamine 

transporter. 

K. Saha, L. Villarroel, P. Davari, S.E. 

Mehr, M.R. Zarindast, B. Richardson and H. 

Khoshbouei. Univ. of Florida and Tehran Univ. of 

Med. Sci. 

(885.4)

4:40 

Cross-talk between beta and alpha 2 adrenergic 

receptors in sympathetic neurons relies on protein 

kinase A and spinophilin. 

C. Cottingham, R. Lu and 

Q. Wang. Univ. of Alabama at Birmingham. (882.2)

5:00 

Keynote Speaker

 

How to do big science on a modest budget: lessons from 

deorphanizing a G protein-coupled receptor. 

L. Devi. 

Mount Sinai Sch. of Med.

PHARMACOLOGY MONDAY

75

M

O

N

272.  MOLECULAR PHARMACOLOGY DIVISION 

POSTDOCTORAL SCIENTIST AWARD 

FINALISTS

Oral

m

on

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 107aB

3:00 

Identification of substituted benzazepines as functionally 

selective ligands of the D

1

 dopamine receptor. 

J.L. 

Conroy, T.B. Doyle and D.R. Sibley. NINDS, NIH, 

Rockville. 

(655.3)

3:30  Development of a membrane-anchored chemerin 

receptor agonist as a novel modulator of inflammation. 

J.R. Doyle, S. Krishnaji, K. Kumar, B. Levy and A.S. 

Kopin. Tufts Med. Ctr., Tufts Univ. and Brigham and 

Women’s Hosp. 

(895.6)

4:00 

Non-canonical signaling by GPCR-arrestin-G

bg ternary 

complexes. 

V.L. Wehbi, T.N. Feinstein and J-P. 

Vilardaga. Univ. of Pittsburgh Sch. of Med. (1172.8)

4:30 

Keynote Speaker

 

Probing G protein coupled receptors: a few of my favorite 

experiments. 

B. Kobilka. Stanford Univ. Sch. of Med.

273.  DRUG DISCOVERY AND DEVELOPMENT: 

GLIOBIOLOGY: EMERGING CONCEPTS IN 

NEURAL-GLIA INTERACTIONS IN CHRONIC 

DISEASE

Symposium

m

on

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 107C

C

haired

: m.F. J

arvis

3:00 

Regulation of myelination by action potentials and an 

introduction to neuron-glia interactions. 

R. D. Fields. 

NICHD, NIH.

3:30 

Reciprocal interactions between motor neurons and 

surrounding astrocytes in ALS. 

J. Weiss. Univ. of 

California, Irvine Sch. of Med.

4:00  Regeneration-related axon and Schwann cell 

interactions. 

D. Zochodne. Univ. of Calgary, Canada.

4:30 

Spinal cord neural-glia interactions in chronic pain. 

R-R. 

Ji. Duke Univ. Med. Ctr.

5:00 

The enigmatic P2X7 channel: physiology, pharmacology 

and implications in CNS disorders. 

A. Bhattacharya. 

Janssen Pharmaceut. Co. of Johnson & Johnson.

274.  LOCAL CA

2+

 SIGNALS IN THE ENDOTHELIUM: 

KEY REGULATORS OF VASCULAR FUNCTION 

AND DYSFUNCTION

Symposium

(Sponsored by: The Division for Cardiovascular 

Pharmacology)

m

on

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 109a

C

haired

: m.t. n

elson

 

anD

 r.m. B

ryan

, J

r

.

3:00 

Multiple roles of endothelial Ca

2+

 signaling in resistance 

networks. 

S. Segal. Univ. of Missouri-Columbia.

3:25  TRPA1-induced endothelial calcium signals and 

vasodilation. 

S. Early. Colorado State Univ.

3:50 

Differential regulation of SK and IK channels during 

endothelium-dependent hyperpolarization. 

K. A. 

Dora. Univ. of Oxford.

4:15 

Elementary TRPV4 Ca

2+

 signals regulate endothelium-

dependent vasodilation. 

S. K. Sonkusare. Univ. of 

Vermont.

4:40 

Endothelial Ca

2+

 wavelets and myoendothelial feedback. 

D. G. Welsh. Univ. of Calgary, Canada.

5:15 

Alteration of endothelial CaMKII in AngII-induced 

hypertensive mice. 

C. Charbel, F. Toussaint, A. 

Blanchette and J. Ledoux. Montreal Heart Inst. and 

Univ. of Montreal. 

(1090.1)

275.  CANADIAN SOCIETY OF PHARMACOLOGY 

AND THERAPEUTICS ANNUAL GENERAL 

MEETING

m

on

. 4:30 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 109B

C

haired

: F. p

arKinson

Experimental Biology exhibitors offer the best tools and  

resources available in research today!

Join the exhibitors at 10:00 

am

 for coffee and 2:00 

pm

 for snacks and  

learn the latest and greatest from more than 300 companies.

MONDAY PHARMACOLOGY

76

APS President’s Symposium Series

From Animals to Human Models of Disease

276.  LESSONS FROM NEW ANIMAL MODELS OF 

CYSTIC FIBROSIS

Symposium

m

on

. 3:15 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 210BC

C

haired

: p. B. m

C

C

ray

Translational Physiology

3:15 

Investigating the pathogenesis of CF lung disease in 

pigs with disruption of the CFTR gene. 

D. Stoltz. Univ. 

of Iowa.

3:45 

Defects in exocrine pancreatic function and lipid 

metabolism: what CF ferrets and pigs are teaching us. 

A. Uc. Univ. of Iowa Carver Col. of Med.

4:15 

Phenotype of the CFTR knockout ferret. 

J. Engelhardt. 

Univ. of Iowa.

4:45 

Lessons learned from tissue-specific manipulation of 

CFTR in mice. 

M. Drumm. Case Western Reserve 

Univ.